Evaluation of efficacy of high dose infliximab with azathiopurine add-on therapy for patients with Crohn's disease refractory to low dose infliximab
Not Applicable
- Conditions
- Crohn's disease
- Registration Number
- JPRN-UMIN000006232
- Lead Sponsor
- Saitama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
patients who cannot been kept in the treatment with infliximab and who cannot been treated with azathiopurine patients in lactate state patient whose age below 15 years old and above 70 years old patients who cannot agree with this study patients who had been treated with open surgery within 6 months patients with short bowel syndrome patients who was determined not to be appropriate in participation in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Remission rate in 24 week
- Secondary Outcome Measures
Name Time Method Remission rates in each state CR70, CR100 Mucosal healing rates in 24, 48 week Loss of response rate Relapse rate Safety